These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23810823)

  • 1. Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology.
    Workman P; Al-Lazikani B; Clarke PA
    Curr Opin Pharmacol; 2013 Aug; 13(4):486-96. PubMed ID: 23810823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
    Smith CIE
    Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular basis of targeting protein kinases in cancer therapeutics.
    Tsai CJ; Nussinov R
    Semin Cancer Biol; 2013 Aug; 23(4):235-42. PubMed ID: 23651790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards precision oncology in RET-aberrant cancers.
    Subbiah V; Roszik J
    Cell Cycle; 2017 May; 16(9):813-814. PubMed ID: 28318386
    [No Abstract]   [Full Text] [Related]  

  • 6. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance.
    Gonzalez de Castro D; Clarke PA; Al-Lazikani B; Workman P
    Clin Pharmacol Ther; 2013 Mar; 93(3):252-9. PubMed ID: 23361103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.
    Messerschmidt JL; Bhattacharya P; Messerschmidt GL
    Curr Oncol Rep; 2017 Aug; 19(10):66. PubMed ID: 28803390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired Resistance Is Oncogene and Drug Agnostic.
    Doebele RC
    Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.
    Mancini M; Yarden Y
    Semin Cell Dev Biol; 2016 Feb; 50():164-76. PubMed ID: 26428295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation.
    Trusolino L; Bertotti A
    Cancer Discov; 2012 Oct; 2(10):876-80. PubMed ID: 23071031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emergence of drug resistance to targeted cancer therapies: Clinical evidence.
    Sarmento-Ribeiro AB; Scorilas A; Gonçalves AC; Efferth T; Trougakos IP
    Drug Resist Updat; 2019 Dec; 47():100646. PubMed ID: 31733611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.
    Rebecca VW; Smalley KS
    Expert Opin Investig Drugs; 2011 Feb; 20(2):137-40. PubMed ID: 21235427
    [No Abstract]   [Full Text] [Related]  

  • 13. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U; Settleman J
    J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.
    Sabnis AJ; Bivona TG
    Trends Mol Med; 2019 Mar; 25(3):185-197. PubMed ID: 30686761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances for studying clonal evolution in cancer.
    Ding L; Raphael BJ; Chen F; Wendl MC
    Cancer Lett; 2013 Nov; 340(2):212-9. PubMed ID: 23353056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic pharmacogenomics in cancer.
    Ikediobi ON
    Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outlier analysis of functional genomic profiles enriches for oncology targets and enables precision medicine.
    Zhu Z; Ihle NT; Rejto PA; Zarrinkar PP
    BMC Genomics; 2016 Jun; 17():455. PubMed ID: 27296290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.
    Angus SP; Zawistowski JS; Johnson GL
    Annu Rev Pharmacol Toxicol; 2018 Jan; 58():209-229. PubMed ID: 28934561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Array-based pharmacogenomics of molecular-targeted therapies in oncology.
    Sanoudou D; Mountzios G; Arvanitis DA; Pectasides D
    Pharmacogenomics J; 2012 Jun; 12(3):185-96. PubMed ID: 22249357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.